button
-
Image
-
Image
Composition
RAZOTM (Rabeprazole sodium Tablets) 20 mg: Each enteric-coated tablet contains Rabeprazole Sodium IP 20 mg with Sodium Bicarbonate as buffer.
Colours: Titanium Oxide & Iron Oxide Yellow.
RAZOTM (Rabeprazole Gastro-resistant Tablets IP 40 mg) 40 mg:Each enteric-coated tablet contains Rabeprazole Sodium IP 40 mg with Sodium Bicarbonate as buffer.
Colours: Red Oxide of Iron, Black Oxide of Iron & Titanium Dioxide IP
How to use?
Razo 20 mg
For healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) 20 mg to be taken once daily for four to eight weeks. Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD). The recommended adult oral dose is one RAZO-IR 20 mg tablet to be taken once daily.
For Healing of Duodenal ulcers and Gastric ulcers: The recommended oral dose for both active Duodenal ulcer and active benign Gastric ulcer is 20 mg to be taken once daily after morning meal.
Razo 40 mg
The recommended adult dosage is 1 tablet once daily or as directed by the Physician. Patients should be cautioned that the Rabeprazole tablets should not be chewed or crushed, but should be swallowed whole. Rabeprazole should be swallowed whole 1 hour before a meal with some water.
Where to use?
Rabeprazole 20 mg is indicated for the treatment of Gastric ulcer, Duodenal ulcer, Zollinger-Ellison Syndrome and GERD.
Rabeprazole 40 mg for the treatment of Gastroesophageal reflux disease, Duodenal ulcer & Zollinger Ellison Syndrome.
What are the side effects?
Adverse Reactions: Proton Pump Inhibitors associated Acute Kidney Injury, the reported ADRs for Rabeprazole were headache, diarrhea, abdominal pain, asthenia, flatulence, rash and dry mouth. Also includes facial swelling, hypotension and dyspnea. Erythema, bullous reactions and hypersensitivity reactions have usually resolved after the discontinuation of therapy. Rare reports of hepatic encephalopathy have been received in patients with underlying cirrhosis. In treatment of patients with severe hepatic dysfunction the prescriber is advised to exercise caution when treatment with Rabeprazole 40 mg Gastro-resistant Tablets is first initiated in such patients. The majority of adverse events experienced during clinical studies were mild or moderate in severity, and transient in nature.
Overdose: Experience to date with deliberate or accidental overdose is limited. The maximum established exposure has not exceeded 60 mg twice daily, or 160 mg once daily. Effects are generally minimal representative of the known adverse event profile and reversible without further medical intervention. No specific antidote is known. Rabeprazole sodium is extensively protein-bound and is, therefore, not dialysable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.
Safety Advice
Contraindications:
Razo 20 mg: It is contraindicated in patients with known hypersensitivity to Rabeprazole, or to any of its components or to substituted benzimidazoles.
Razo 40 mg: Hypersensitivity to the active substance, or to any of the excipients. - Pregnancy, and - Breastfeeding.
Special Warnings and Precautions for Use:
Razo 20 mg: Patients on long-term treatment (> 1 year) should be kept under regular surveillance. Co-administration of Atazanavir with Rabeprazole is not recommended. Severe hypomagnesaemia has been reported in patients treated with PPIs like Rabeprazole for at least three months, and in most cases for a year. Concomitant use of PPIs with methotrexate may elevate and prolong serum levels of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities. It may reduce the absorption of vitamin B12 due to hypo- or a-chlorhydria.
Razo 40 mg: Symptomatic response to therapy with Rabeprazole sodium does not preclude the presence of gastric or oesophageal malignancy, therefore the possibility of malignancy should be excluded prior to commencing treatment with Rabeprazole. Patients on long-term treatment (particularly those treated for more than a year) should be kept under regular surveillance. A risk of cross-hypersensitivity reactions with other proton pump inhibitors or substituted benzimidazoles cannot be excluded.
Use in specific populations: pregnancy: It is contraindicated during pregnancy.
Breast-feeding: It is not known whether Rabeprazole sodium is excreted in human breast milk. No studies on lactating women have been performed. Rabeprazole sodium is however, excreted in rat mammary secretions. Therefore, Rabeprazole 40mg enteric coated tablet must not be used during breastfeeding.
Use in Children: Rabeprazole tablets are not recommended for use in children due to a lack of data on safety and efficacy.
Paediatric population: Rabeprazole tablets are not recommended for use in children due to a lack of data on safety and efficacy.
Renal and hepatic impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment.
For the use of a Registered Medical Practitioner, Hospital or Laboratory only. Images appearing herein are for illustration purposes only.
Please refer to the product label for more information
Supporting You & Your Patients
Videos Speakers
Knowledge Hub
-
An Approach to APD and its Management
Read More
GGI-CO-A1-AQS-300021212-WM-I23-0056
Below fields are needed for webinar purpose.